Livia Stanger and Colleagues Link CS014 to in Vivo Thrombosis
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis
CS014, a novel HDAC inhibitor, prevents blood clots as effectively as valproic acid but without hepatotoxic metabolites, offering safer antithrombotic therapy without increasing bleeding risk.”
Read the full article here.
Article: Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis
Authors: Livia Stanger, Pooja Yalavarthi, Reheman Adili, Devin Gilmore, Timothy Hoang, Avery Campbell, Paul Krenik, David Gustafsson, Jan Fryklund, Tomas Fex, Nicholas Oakes, Jonas Faijerson Säljö, Björn Dahlöf, Joan Beckman, Michael Holinstat
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025
-
Mar 12, 2026, 16:36Giordano Botta: From the ‘Power of Zero’ to a Precise Understanding of Cardiovascular Risk
-
Mar 12, 2026, 16:31Katie Baca-Motes: Incorporating Menstrual Cycle and Hormonal Rhythms Into Clinical Research
-
Mar 12, 2026, 16:22Augustina Isioma Ikusemoro: Quality Indicators in Processed Blood Components
-
Mar 12, 2026, 16:20Aryabhatta Sadhu: The Full Spectrum of Transplant Immunology and Clinical Care
-
Mar 12, 2026, 16:17Megan Adediran: Building Pathways to Sustainable Care for People With Bleeding Disorders in Nigeria
-
Mar 12, 2026, 16:09Rob Mac Sweeney: Hemodynamic Failure During Sepsis
-
Mar 12, 2026, 16:06Haroun Gajraj: Shortwave Diathermy for Facial Spider Veins